Superior 220 15 Elmira 320 Others Receiving Votes StI just hope Shane Carwin doesn't read thisFelt we could of had alot more from Deco and more from Drogba tooThe higheryielding Australian dollar lost 2They donrsquot do well in Washington eitherFact is the trapezoid has done more harm than goodThe ILLUMINATE trial enrolled approximately 500 patientsbut he hasnrsquot scored in four weeks. PlusDepartment ofHealth and Human Services HHSWhether you like it or not it's here to staySince its launch, "The View" has received 24 DaytimeEmmy Awards, including Outstanding Talk Show. The program is broadcast in HDTV with 5.1-channelsurround sound and is currently in its 12th season on ABC.SOURCEKimberly-Clark CorporationKristin Neuckranz, 1-312-228-6866, , forKimberly-Clark Corporation; or Joey Mooring of Kimberly-Clark Corporation,1-972-281-1443, ; or Karl Nilsson of ABC,1-212-456-7955, . ESPN's Adam Schefter reported that NFL&hl158411&id4149" title"Brady Quinn" target"blank">Brady Quinn will finally be inserted back into Cleveland's starting lineup, and the horrid Derek Anderson will take his place where he belongs, back on the Browns' bench.After getting yanked just two and a half games into his first season as the full-time starter, Quinn is getting one more shot to prove to the franchise that drafted him that he's still worth keeping around.There had been speculation early in the season that Eric Mangini had always been a Derek Anderson supporter, albeit silently, and secretly wanted Quinn to fail, although the front office wanted their former first rounder to get the first crack at the job.In addition to this theory, there is also speculation that Quinn was benched more due to contractual incentives, rather than his performance.Regardless of the reason of his original benching, Quinn is back in the lineup, and can't do much worse than Anderson has done over the last six games.Fantasy Perspective: There isn't a fantasy perspective Not if we're being honest with Cleveland fans. The only guy worth mentioning that Quinn could call a "weapon" is now a New York Jet, and Mohamed Massaquoi, a talented rookie receiver, drops too many passes to be relied upon.It probably woudn't matter what Quinn's supporting cast looked like, however, as his match-up against the Baltimore Ravens is already a brutal enough "welcome back."For more NFL breaking news and fantasy updates, go to NFLSoup . PrivateBancorp, Inc. 
to Ring NASDAQ Opening Bell and Host InstitutionalInvestor DayCHICAGO, Jan. Richman, President and ChiefExecutive Officer, will ring The NASDAQ Stock Market opening bell on Thursday,February 19, 2009 at 9:30 a.m. EST at NASDAQ's MarketSite in Times Square inNew York City."We are truly pleased to celebrate our 20th year of business and our 10thyear as a public company by ringing the NASDAQ opening bell.Since ourinitial public offering in 1999, we have recognized many successes in themarketplace and we continue to work diligently toward our goal of increasinglong-term shareholder value," said Larry D. EST at the Sofitel New York, located at 45 West 44th Street in NewYork City.The Investor Day will include a keynote address from Mr.
Richman,a financial and risk management update from management and a panel discussionwith the company's line of business leaders.The Investor Day will be webcastvia a link available at http:// contact Katie Manzel in Investor Relations at 312-564-6818 or to register for attendance at the Investor Day by Wednesday,February 11, 2009.To view the NASDAQ opening bell ceremony live, visit http:// to access the MarketSiteweb cam link.About PrivateBancorp, Inc.PrivateBancorp, Inc. WaferGen's SmartChip(TM) System Performance Successfully Demonstrated inInitial Phase of Alpha Testing ProgramFREMONT, Calif., Jan 12 /PRNewswire-FirstCall/ WaferGen Biosystems,Inc. (OTC Bulletin Board: WGBS), a leading developer of state-of-the-art geneexpression, genotyping, cell biology and stem cell research systems, todayannounced that academic researchers have successfully demonstrated theperformance of the company's SmartChip(TM) Real-Time PCR System in the initialphase of the platform's ongoing alpha testing program.Initial testsconducted at the University of Pittsburgh School of Medicine have demonstrateda number of the SmartChip system's key analytical specifications, showing theproduct's complete workflow on 1,000 oncology genes using small amounts ofsamples from emphysema, idiopathic pulmonary fibrosis (IPF) and healthypatients.Key workflow elements that have been successfully demonstrated includeprimer-ready SmartChips and the drying and reconstitution of primers for rapidhigh-throughput 100 nL real-time polymerase chain reaction (PCR).Additionally, the platform's ability to perform PCR in nano-volumes withoutany pre-amplification has been demonstrated using various control genes, aswell as indicators of other genes that are known to be expressed in patientsamples.The next phase of the alpha testing program will focus on using theSmartChip system to identify biomarkers of interest.Upon completion of theongoing alpha testing program, data will be presented and/or published inappropriate academic venues."The successful demonstration of the performance of the revolutionarySmartChip system in a rigorous research setting is a tremendous step forwardfor this novel platform.We are particularly excited that the platform hasshown the ability to capture the expression of genes that have not been ableto be seen using microarrays," stated Alnoor Shivji, WaferGen's chairman andchief executive officer."We expect that this is just the first milestonerelated to the SmartChip alpha testing program and look forward to newfindings on biomarker discovery and validation."The SmartChip alpha testing program involves the study of RNA isolatedfrom lung tissue samples from healthy patients, as well as patients withchronic obstructive pulmonary disease (COPD) and IPF.Researchers arescreening these RNA samples with the SmartChip Real-Time PCR System in orderto assess the platform's performance in conducting novel gene expressionresearch.About the SmartChip Real-Time PCR SystemThe SmartChip Real-Time PCR System(TM) is designed as the first wholegenome, high-throughput gene expression real-time PCR platform.Thisinnovative system, combined with next-generation chemistry and optimizedassays being developed by WaferGen, promises to deliver significant speed andcost advantages to researchers in the gene expression and genotyping markets.Based on collaborations established with leading research institutions,WaferGen believes that the SmartChip Real-Time PCR System is positioned as theplatform of choice for biomarker discovery and validation.It is estimatedthat the genetic analysis market alone (comprised of gene expression andgenotyping analysis) had approximately $2.4 billion in worldwide revenues in2006 ($1.74 billion for gene expression and $650 million for genotyping).Total global revenue for this market is estimated to reach approximately $5.0billion by 2012.WaferGen believes the SmartChip Real-Time PCR System will be the firstplatform to combine the high-throughput capability and cost efficiencies ofexisting microarrays, with the sensitivity and accuracy of real-time PCR.Specifically, the SmartChip Real-Time PCR System's high density, rapid cyclingconfiguration is expected to provide industry-leading throughput levels, whileoffering discovery and validation capabilities in a single step.The resultwill be the ability to conduct gene expression research at a fraction of thetime and cost currently produced by existing instrument systems.Thisdecrease in research time has broad economic implications across the drugdevelopment industry, particularly for pharmaceutical companies seekingavenues for reducing time to market for their therapeutics.Further, thecompany believes such throughput will dramatically impact the cost of suchassays.Beyond the significant time and cost advantages, the simplicity of theSmartChip Real-Time PCR System is unparalleled.The system will provide anumber of key ease-of-use features including content-ready chips with genepanels optimized for cancer, toxicology and whole genome.The user-friendlySmartChip Real-Time PCR System will be preloaded with some of the reactioncomponents. At the same time, the system will only require a very small samplesize as compared to other technologies and platforms and will offer real-timedetection and sophisticated read-out options while assuring quantitativereal-time PCR performance.About WaferGenWaferGen Biosystems, Inc. is a leader in the development, manufacture andsale of state-of-the-art systems for gene expression, genotyping, cell biologyand stem cell research for the life science and pharmaceutical industries. Thecompany is actively developing its SmartChip(TM) product for the geneexpression and genotyping markets.
SmartChip is being developed as the firstwhole genome, high throughput gene expression real-time polymerase chainreaction (PCR) platform. This innovative system, combined with next-generationchemistry and optimized assays being developed by WaferGen, promises todeliver significant speed and cost advantages to researchers in the geneexpression and genotyping markets. Based on collaborations established withleading research institutions, WaferGen believes that the SmartChip Real-TimePCR System is positioned as the platform of choice for biomarker discovery andvalidation.WaferGen currently markets its SmartSlide(TM) family of productsto companies and organizations involved in stem cell and cell biologyresearch. Representative SmartSlide customers include Harvard University, MayoClinic, California Institute of Technology (CalTech), Abbott Labs, and theNational Institutes of Health (NIH).Forward-Looking StatementsThis press release contains certain "forward-looking statements". Suchstatements include statements relating to the company's goals, plans andprojections, anticipated results of research, performance, reliability andcost-effectiveness of the company's SmartChip and other systems, and otherstatements that are not historical facts, including statements which may bepreceded by the words "intends," "may," "will," "plans," "expects,""anticipates," "projects," "predicts," "estimates," "aims," "believes,""hopes," "potential" or similar words.Forward-looking statements are not guarantees of future performance, arebased on certain assumptions and are subject to various known and unknownrisks and uncertainties, many of which are beyond the control of the company.Actual results may differ materially from the expectations contained in theforward-looking statements. Factors that may cause such differences includethe risks that: (i) the company may be unsuccessful in commercially developingits products or in achieving market acceptance of new and relatively unproventechnologies; (ii) the company will need to raise additional capital to meetits business requirements in the future and the company may not be able to doso on reasonable terms or at all; (iii) the company's proprietary intellectualproperty rights may not adequately protect its products and technologies; and(iv) the company expects intense competition in its target markets, includingfrom companies that have much greater resources than the company, and therecan be no assurance that the company will be able to compete effectively.More detailed information about the company and the risk factors that mayaffect the realization of forward-looking statements is set forth in thecompany's filings with the Securities and Exchange Commission, including thecompany's Annual Report on Form 10-K for the year ended December 31, 2007, andits subsequent Quarterly Reports on Form 10-Q filed with the SEC.
